Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PEGFILGRASTIM

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (L03AA) — coverage varies; not interchangeable

  • Filgrastim (Nivestym): general benefit

Lapelga · DIN 02529343 · 6mg/0.6mL · injection solution-0.6mL Pref Autoinj (Preservative-Free)

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Lapelga · DIN 02529343 Manufacturer: Apotex Inc.; listing date 2023-09-28 Health Canada: Marketed since 2022-11-28 · brand LAPELGA · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 6 MG/0.6ML · company Apotex inc · schedule Prescription, Schedule d
Check this DIN again · Health Canada product record

Lapelga: Formulary list price $1375.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1375.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101856 · Verify on the e-Formulary ↗ (DIN 02529343)

Source record
DIN 02529343: Lapelga Raw flags: sec3=Y Item: 201600064; group id 270; item number 0554; lccId None; manufacturer id APX Source form: Inj Sol-0.6mL Pref Autoinj (Preservative-Free); strength: 6mg/0.6mL Recorded listing: General benefit Source prices (unrounded): $1375.0000; ministry $1375.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02529343 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101856
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529343
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Niopeg · DIN 02546973 · 6mg/0.6mL · injection, 0.6 mL pre-filled syringe (preservative-free)

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Niopeg · DIN 02546973 Manufacturer: Nora Pharma; listing date 2025-07-31 Health Canada: Marketed since 2025-02-12 · brand NIOPEG · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 6 MG/0.6ML · company Nora pharma inc · schedule Prescription, Schedule d
Check this DIN again · Health Canada product record

Niopeg: Formulary list price $492.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $492.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103564 · Verify on the e-Formulary ↗ (DIN 02546973)

Source record
DIN 02546973: Niopeg Raw flags: sec3=Y Item: 201600069; group id 270; item number 0556; lccId None; manufacturer id NRA Source form: Inj Sol-0.6mL Pref Syr (Preservative-Free); strength: 6mg/0.6mL Recorded listing: General benefit Source prices (unrounded): $492.0000; ministry $492.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02546973 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103564
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02546973
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pexegra · DIN 02553945 · 6mg/0.6mL · injection, 0.6 mL pre-filled syringe (preservative-free)

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Pexegra · DIN 02553945 Manufacturer: Jamp Pharma Corporation; listing date 2025-07-31 Health Canada: Marketed since 2025-09-09 · brand PEXEGRA · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 10 MG/ML · company Jamp pharma corporation · schedule Prescription, Schedule d
Check this DIN again · Health Canada product record

Pexegra: Formulary list price $492.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $492.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104284 · Verify on the e-Formulary ↗ (DIN 02553945)

Source record
DIN 02553945: Pexegra Raw flags: sec3=Y Item: 201600070; group id 270; item number 0557; lccId None; manufacturer id JPC Source form: Inj Sol-0.6mL Pref Syr (Preservative-Free); strength: 6mg/0.6mL Recorded listing: General benefit Source prices (unrounded): $492.0000; ministry $492.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553945 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104284
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02553945
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ziextenzo · DIN 02497395 · 6mg/0.6mL · injection, 0.6 mL pre-filled syringe (preservative-free)

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Ziextenzo · DIN 02497395 Manufacturer: Sandoz Canada Inc.; listing date 2020-08-28 Health Canada: Marketed since 2020-05-15 · brand ZIEXTENZO · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 6 MG/0.6ML · company Sandoz canada incorporated · schedule Schedule d, Prescription
Check this DIN again · Health Canada product record

Ziextenzo: Formulary list price $492.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $492.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98722 · Verify on the e-Formulary ↗ (DIN 02497395)

Source record
DIN 02497395: Ziextenzo Raw flags: sec3=Y Item: 201600060; group id 270; item number 0555; lccId None; manufacturer id SDZ Source form: Inj Sol-0.6mL Pref Syr (Preservative-Free); strength: 6mg/0.6mL Recorded listing: General benefit Source prices (unrounded): $492.0000; ministry $492.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02497395 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98722
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02497395
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nyvepria · DIN 02506238 · 6mg/0.6mL · injection solution-0.6mL pre-filled syringe Pk (Preservative-Free)

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Nyvepria · DIN 02506238 Manufacturer: Pfizer Canada Inc.; listing date 2021-08-31 Health Canada: Marketed since 2021-01-18 · brand NYVEPRIA · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 6 MG/0.6ML · company Pfizer canada ulc · schedule Prescription, Schedule d
Check this DIN again · Health Canada product record

Nyvepria: Formulary list price $1375.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1375.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99556 · Verify on the e-Formulary ↗ (DIN 02506238)

Source record
DIN 02506238: Nyvepria Raw flags: sec3=Y Item: 201600061; group id 270; item number 0558; lccId None; manufacturer id PFI Source form: Inj Sol-0.6mL Pref Syr Pk (Preservative-Free); strength: 6mg/0.6mL Recorded listing: General benefit Source prices (unrounded): $1375.0000; ministry $1375.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02506238 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99556
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02506238
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Fulphila · DIN 02484153 · 10mg/mL · injection, pre-filled syringe

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Fulphila · DIN 02484153 Manufacturer: Biosimilar Collaborations Ireland Limited; listing date 2020-05-29 Health Canada: Marketed since 2026-08-14 · brand FULPHILA · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 10 MG/ML · company Biocon biologics canada inc · schedule Prescription, Schedule d
Check this DIN again · Health Canada product record

Fulphila: Formulary list price $492.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $492.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97449 · Verify on the e-Formulary ↗ (DIN 02484153)

Source record
DIN 02484153: Fulphila Raw flags: sec3=Y Item: 201600055; group id 270; item number 0559; lccId None; manufacturer id BCL Source form: Inj Sol-Pref Syr; strength: 10mg/mL Recorded listing: General benefit Source prices (unrounded): $492.0000; ministry $492.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02484153 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97449
Shortage status: resolved shortage (ended 2023-03-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02484153
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lapelga · DIN 02474565 · 10mg/mL · injection, pre-filled syringe - 0.6mL Pk (Preservative Free)

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Lapelga · DIN 02474565 Manufacturer: Apotex Inc.; listing date 2019-08-30 Health Canada: Marketed since 2019-02-27 · brand LAPELGA · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 6 MG/0.6ML · company Apotex inc · schedule Schedule d, Prescription
Check this DIN again · Health Canada product record

Lapelga: Formulary list price $492.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $492.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96479 · Verify on the e-Formulary ↗ (DIN 02474565)

Source record
DIN 02474565: Lapelga Raw flags: sec3=Y Item: 201600054; group id 270; item number 0560; lccId None; manufacturer id APX Source form: Inj Sol-Pref Syr - 0.6mL Pk (Preservative Free); strength: 10mg/mL Recorded listing: General benefit Source prices (unrounded): $492.0000; ministry $492.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474565 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96479
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474565
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (20:16 Hematopoietic Agents) and how they are covered

Matched class: 20:16 Hematopoietic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FILGRASTIM 20:16 Hematopoietic Agents

FILGRASTIM

· 10 products · General benefit · strengths: 300mcg/0.5mL, 480mcg/0.8mL, 480mcg/1.6mL, 300mcg/mL · Inj Sol-0.5mL Pref Syr, Inj Sol-0.5mL Pref Syr (Preservative-Free), Inj Sol-0.8mL Pref Syr, Inj Sol-0.8mL Pref Syr (Preservative-Free), Inj Sol-1.6mL Vial Pk, Inj Sol-1mL Vial Pk, Pref Syr-0.5mL Pk, Pref Syr-0.8mL Pk

DARBEPOETIN ALFA

· 4 products · Limited Use, codes 420 · strengths: 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/1.0mL · Pref Syr-0.3mL Pk, Pref Syr-0.4mL Pk, Pref Syr-0.6mL Pk, Pref Syr-1.0mL Pk

EPOETIN ALFA

· 3 products · Limited Use, codes 420 · strengths: 10,000IU/mL, 40,000IU/mL, 20,000IU/0.5mL · Pref Syr - 1mL Pk, Pref Syr-0.5mL Pk

ELTROMBOPAG OLAMINE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:16
Full class listing Related classes: 20:04 Antianemia Drugs, 20:12 Coagulants and Anti-Coagulants, 20:24 Hemorrheologic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications LAPELGA® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti- neoplastic drugs. 1.1 Pediatrics (< 18 years of age) No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics (> 65 year of age) No data are available to Health Canada; therefore Health Canada has not authorized on indication for geriatric use. https://pdf.hres.ca/dpd_pm/00083321.PDF PM date: 2026-01-29 Source product: LAPELGA; DIN 02474565; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.